American Society of Hirudotherapy

Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1beta and glucocorticoids

Research article published in Arthritis and rheumatism (2004)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportGenomics & ProteomicsToh ML et al. · Arthritis and rheumatism, 2004

Abstract

OBJECTIVE: Mitogen-activated protein kinases (MAPKs) are activated by proinflammatory stimuli. MAPK phosphatases (MKPs), in particular MKP-1, have been identified as endogenous negative regulators of MAPK activation. Since MAPKs are known to be important in rheumatoid arthritis (RA) synoviocyte activation, this study assessed the expression, regulation, and function of MKP-1 in RA. METHODS: MKP-1 expression was measured by Western blotting (WB) and real-time polymerase chain reaction (PCR). RA fibroblast-like synoviocytes (FLS) were treated with interleukin-1beta (IL-1beta), tumor necrosis factor alpha, fetal calf serum, and dexamethasone. Expression of MAPKs in RA FLS was analyzed by WB using phosphospecific antibodies, while IL-6 expression was assessed by real-time PCR. RESULTS: MKP-1 protein and messenger RNA were detected in cultured RA FLS. IL-1beta rapidly up-regulated MKP-1, coinciding with reciprocal down-regulation of ERK, JNK, and p38 MAPK phosphorylation. Dexamethasone rapidly and sustainably up-regulated MKP-1, and this also coincided with down-regulation of ERK, JNK, and p38 MAPK phosphorylation. In addition, dexamethasone augmented IL-1beta-induced up-regulation of MKP-1, and this was associated with inhibition of ERK, JNK, and p38 MAPK phosphorylation and IL-6 expression. Dexamethasone had no effect on the phosphorylation of upstream kinases such as MEKK-3/6. In the presence of glucocorticoid (GC) receptor antagonist RU 486, the dexamethasone-mediated up-regulation of MKP-1 was impaired. Moreover, inhibition of MKP-1 expression impaired dexamethasone-mediated inhibition of MAPK phosphorylation. CONCLUSION: This study demonstrates the expression of MKP-1 in RA FLS. Cytokine and GC regulation of MKP-1 may be important in determining the magnitude of the inflammatory response in RA that is mediated via MAPKs. The effects of GCs in RA may be mediated, in part, via GC receptor-dependent up-regulation of MKP-1.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsArthritis, RheumatoidBlotting, WesternCells, CulturedDexamethasoneDual Specificity Phosphatase 1GlucocorticoidsHumansInterleukin-1MifepristoneMitogen-Activated Protein KinasesPhosphorylationPolymerase Chain Reaction

Summary

Mitogen-activated protein kinases (MAPKs) are activated by proinflammatory stimuli.

Why This Matters for Hirudotherapy

This study examined the expression, regulation, and function of MAPK phosphatase-1 (MKP-1) in cultured rheumatoid arthritis (RA) fibroblast-like synoviocytes, finding that interleukin-1beta and dexamethasone upregulate MKP-1 with reciprocal downregulation of ERK, JNK, and p38 MAPK phosphorylation. This work elucidates inflammatory signaling pathways in RA synoviocytes that could, in principle, intersect with mechanisms relevant to anti-inflammatory effects attributed to leech-derived factors in complementary medicine contexts. However, there is no mention of leeches, hirudotherapy, leech secretome components, or any leech-derived substance anywhere in the abstract. The relevance to ASH's domain is therefore essentially nonexistent based on this abstract alone.

Citation

Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1beta and glucocorticoids

Toh ML et al. · Arthritis and rheumatism, 2004

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.